MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2018 International Congress

    It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

    M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

    Objective: This study determined the efficacy of internally guided (leading) versus externally guided (following) in adapted tango versus a contact-matched control group (wellness education) for…
  • 2018 International Congress

    Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

    Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…
  • 2018 International Congress

    Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

    V. Kumar (Allahabad, India)

    Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…
  • 2017 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
  • 2017 International Congress

    Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study

    S. Sharma, T. Simuni, B. Greco, K. Biglan, C. Tarolli, K. Hodgeman, D. Oakes, D. Penz (Rochester, NY, USA)

    Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…
  • 2017 International Congress

    Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker

    B. McMicken (Irvine,  , CA, USA)

    Objective: Congenital aglossia is a rare syndrome of born without a tongue. This paper examines  articulatory movements of a congenital aglossic speaker to understand  physiology by…
  • 2017 International Congress

    The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine

    K. Romero, D. Conrado, B. Corrigan, K. Tsai, M. Ahamadi, S. Macha, V. Sinha, I. Watson, M. Bani, P. Muglia, V. Kern, C. Williams-Gray, D. Grosset, M. Hu, D. Burn, R. Lawson, K. Marek, A. Roach, D. Stephenson, T. Nicholas (Tucson, AZ, USA)

    Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…
  • 2017 International Congress

    Treatable Rare Movement Disorders

    E. Gatto, H. Jinnah, A. Espay, J. Jankovic, K. Bhatia, M. Rodriguez, V. Fung, F. Cardoso, M. Rodriguez Oroz, A. Albanese, A. Muenchau, A. Chade, M. de Koning-Tijssen, M. Stamelou, P. Garcia Ruiz, C. Uribe Roca, F. Morgante, A. Dela Cerda, L. Schoels, J. Miyasaki, J. Ferreira (Buenos Aires, Argentina)

    Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and  others Background: Rare diseases (RD)…
  • 2017 International Congress

    Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression

    N. Kanzato (Haebaru-cho, Japan)

    Objective: To evaluate to predictors of the disease-modifying effect of drugs on Parkinson’s disease (DM-PD) according to long-term therapeutic investigation, especially regarding the non-dopaminergic agent…
  • 2017 International Congress

    Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

    E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

    Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley